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Specific Aim: My specific aim is 
to modify Amyloid-Beta 40 
(Aβ40) and Amyloid-Beta 42 
(Aβ42). This is so the proteins 
will not interfere with neuronal 
signaling. This modification 
should act as a therapy for 
patients.  
Neuronal Cultures
• Collect rat embryos and extract their Hippocampus and Cortical tissue. Add 2.5% 
Trypsin to dissociate the cells. Place cells in 384-poly D-Lysine coated plates with 
Neurobasal Media, Glutamax, and antibiotics
Trafficking Assay 
• With the compounds and Abeta40 & Abeta42 oligomer preparations, treat the 
neurons. Incubate at 37 Celsius in 5% of CO2 for 24 hours. Add Tetrazolium salts to 
the final concentration of 0.75 mm. Incubate the solution for 60 minutes.
Preparations for 
Amyloid Oligomers
• Evaporate the 1,1,1,3,3,3,hexafluoro-2-propanol from a solution of 0.253 mg Abeta
40/42 to prepare Abeta monomer film. Dissolve film in DMSO and dilute to 100 mM
with cold Basal Media Eagle media. Incubate at 4 degrees Celsius to make oligomers. 
Abeta Binding 
Assay 
• For Synthetic Abeta 40/42 oligomer preparation, add oligomers an hour prior to the 
compounds. For 15 minutes, fix the cells with 0.5% of Triton X-1003, .75% formaldehyde 
and block with 5% goat serum. Incubate with the primary antibodies for Synaptophysin-
1, glial fibrillary acidic protein and Abeta, MAP-2. 
Synapse Counting 
Assay 
• Before adding 6 mM of synthetic Abeta 40/42 oligomers, treat cultures with 
compounds. Then, incubate for 24 hours. Use the ThermoFisher/Cellomics Neuronal 
Profiling bio application to count the synaptophysin-immunopositive puncta . 
Statistical Assay
• The well averages will be looked at with the KS distance test. The Abeta 40/42 
oligomers will be observed with the Western Blot Analysis. The treatment 
differences will be looked at with One-way ANOVA.
Figure 4. Plaques and Tangles 
These illustrations display the process of how plaques and tangles function in the brain. A. 
The top picture shows where plaques are located on the nueron. The bottom picture shows 
how tau are attached to the microtubules. B. This illustration shows the atrophic affects of 
the brain from plaques and tangles.
Figure 3. Hippocampal/cortical cultures immunofluorescent labeling.
A. Labeled MAP2 neurons. B. Labeled DAPI nuclei. C. Labeled GFAP glia and Nuclei. D. 
This image displays the merging parts of all three images. The percentage of neurons 
was 26.0 ± 1.1% in the cultures. This was based on the untreated control wells. (Izzo 
2014) The primary rat neurons can replicate the electrophysiological state-dependent 
signaling.
Potential Pitfalls: 
• Creating a therapy could cause issues with patients. 
• There could possibly be failure to provide therapeutic benefits for patients with 
Alzheimer’s Disease. 
• There could also be a failure in therapy if the patient has undergone too much 
neuronal loss. 
Potential Conclusions: 
• The symptoms of neurodegeneration could decrease with modifications done to the 
Amyloid Beta-40 and 42 proteins. 
• This could serve as a therapy for AD patients and save people from losing their 
memory entirely.
• A cure still hasn’t been found for Alzheimer’s, so it’s important to continue 
researching this insufferable disease. 
• Alzheimer Disease is the most 
common cause of Dementia, 
which slowly deteriorates the 
brain. 
• Tangles and Plaques are two 
major components in the 
process of Alzheimer’s. 
• Plaques and Tangles interfere 
with neuron signaling in the 
brain, which can lead to memory 
impairment. 
• There are two specific groups of 
AD. Familial, which is early onset 
and Sporadic, which is late 
onset.
• Amyloid-Beta 40 (Aβ40) and 
Amyloid-Beta 42 (Aβ42) are 
responsible for 
neurodegeneration and age-
dependent learning defects.
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Figure 1. Alzheimer’s Disease Facts 
Alzheimer’s Disease affects 1 in 3 seniors, 
and is the 6th leading cause of death in the 
United States.
Figure 2. Impacts on the brain
On the left side, this figure displays the 
atrophic affects of Alzheimer’s Disease. The 
right side displays a healthy brain. 
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